Novartis Announced That The European Commission (Ec) Approved Tabrecta (Capmatinib) As A Monotherapy For The Treatment Of Adults With Advanced Non-Small Cell Lung Cancer (Nsclc) Harbouring Alterations Leading To Mesenchymal-Epithelial-Transition Factor Gene (Met) Exon 14 (Metex14) Skipping Who Require Systemic Therapy Following Prior Treatment With Immunotherapy And/Or Platinum-Based Chemotherapy.The Approval Follows A Positive Opinion Issued In April By The Committee For Medicinal Products For Human Use (Chmp) Of The European Medicines Agency (Ema) And Is Applicable To All 27 European Union Member States Plus Iceland, Norway And Liechtenstein.
